85336-17-0

Basic information

• Product Name: Benzenamine, 5-(1,1-dimethylethyl)-2-methyl-
• Synonyms: Benzenamine, 5-(1,1-dimethylethyl)-2-methyl-;5-tert-Butyl-2-methylphenylamine
• CAS NO: 85336-17-0
• Molecular Formula: C₁₁H₁₇N
• Molecular Weight: 163.26
• Mol File: 85336-17-0.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzenamine, 5-(1,1-dimethylethyl)-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 5-(1,1-dimethylethyl)-2-methyl-(85336-17-0)
• EPA Substance Registry System: Benzenamine, 5-(1,1-dimethylethyl)-2-methyl-(85336-17-0)

Safety Data

• Hazardous Substances Data: 85336-17-0(Hazardous Substances Data)

Upstream product

• 62559-08-4 4-tert-butyl-2-nitrotoluene 
• 98-51-1 4-tert-butyltoluene 
• 61024-94-0 2-bromo-4-tert-butyl-1-methylbenzene 

Downstream Products

• 5781-02-2 5-(tert-butyl)-2-methylphenol 
• 70728-98-2 4-(tert-butyl)-2-iodo-1-methylbenzene 
• 207737-25-5 5-tert-butyl-2-methyl-4-thiocyanatophenylamine 
• 261711-84-6 Boc-protected 3-tert-butyl-6-methylanilin 
• 263843-06-7 ethylsulfamic acid 4-{6-[2-(4-aminophenyl)ethyl]-4-hydroxy-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-5-tert-butyl-2-methylphenyl ester hydrochloride 
• 263842-92-8 4-cyano-benzenesulfonic acid 5-tert-butyl-4-{6-cyclohexyl-4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester 
• 263842-91-7 benzenesulfonic acid 5-tert-butyl-4-{6-cyclohexyl-4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester 
• 263842-84-8 4-cyano-benzenesulfonic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester 
• 263842-83-7 4-fluoro-benzenesulfonic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester 
• 263842-90-6 4-Fluoro-benzenesulfonic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-methyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester 
• 263842-88-2 pyridine-3-sulfonic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester 
• 263842-82-6 benzenesulfonic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester 

Relevant articles and documents

METHOD FOR CONVERTING HYDROXYL GROUP OF ALCOHOL

The present invention relates to: a method for converting a hydroxyl group of an alcohol; and a catalyst which makes the method possible. A method for converting a hydroxyl group of an alcohol according to the present invention is characterized by producing a compound represented by CH(R1)(R2)Nu (wherein R1, R2 and Nu are as defined below) by reacting an alcohol represented by CH(R1)(R2)OH (wherein each of R1 and R2 represents a hydrogen atom, an optionally substituted alkyl group, or the like) and a compound having an active proton, which is represented by H-Nu (wherein Nu represents a group represented by —CHX1-EWG1 or —NR3R4; X1 represents a hydrogen atom or the like; EWG1 represents an electron-withdrawing group; and each of R3 and R4 represents a hydrogen atom, an optionally substituted alkyl group, or the like), with each other in the presence of a complex of a group 7-11 metal of the periodic table and at least one solid base that is selected from the group consisting of layered double hydroxides, composite oxides and calcium hydroxide.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS

A compound of formula (I): wherein either B is absent and A and Z are the same or different and are each hydrogen, halogen, alkyl, hydroxy, alkoxy,-CN,-C(Rc)2OH,-N(Rd)C(=X)Rc,-C(=X)N(Rc)(Rd),-S(O)m-Rc,-N(Rc)(Rd)S(O)2,-S(O)2N(R c)(Rd),-N(Re)2, aryl optionally substituted with Ra or-O-aryl optionally substituted with Ra; or B is present and is-(CH2)n-,-C(Rb)2-or-O-, or B taken together with A or Z can be-C=C(Rb)-,-C(Rb)=C-,-CH2-CH(R b)-or-CH(Rb)-CH2-; D is-O-or-S(O) m,-; E is a bond or is-(CH2)n-,-N(R d)-,-(CH2)nN(Rd)-or-N(R d)(CH2)n-; F is-C(=X)-; G is-(CH2 )n-,-N(Rd)-,-(CH2)nN(R d)-or-N(Rd)(CH2)n; J is a bond,-O-,-N(RC)C(=X)-,-C(=X)N(Rc)-,-S(O)m,-,-N(Rc)S(O)m-,-S(O)nN(Rc)-,-N(Re)-or-N(Rg)(Rh); K is a bond, alkylene, cycloalkylene, cycloalkenylene, arylene, heterocycloalkylene, heterocycloalkylene or heteroarylene; and L is hydrogen or a terminal group; has therapeutic utility.